Cargando…

19. Completion of Two-Dose Recombinant Zoster Vaccine Series in Adults 50 Years and Older

BACKGROUND: In 2017, the Advisory Committee on Immunization Practices preferentially recommended adjuvanted recombinant zoster vaccine (RZV) for adults ≥ 50 years as a two-dose series 2–6 months apart.(1) We evaluated two-dose RZV completion and factors associated with completion. METHODS: The study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tseng, Hung-Fu, Qian, Lei, Wu, Jun, Luo, Yi, Sy, Lina S, Bruxvoort, Katia, Ackerson, Bradley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776052/ http://dx.doi.org/10.1093/ofid/ofaa439.064

Ejemplares similares

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

2300. Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated Adults ≥50 Years of Age
por: Ackerson, Bradley, et al.
Publicado: (2019)

The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence
por: Tseng, Hung Fu, et al.
Publicado: (2020)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

Association of Number of Doses With Hepatitis B Vaccine Series Completion in US Adults
por: Bruxvoort, Katia, et al.
Publicado: (2020)

1156. Real-World Effectiveness of Recombinant Zoster Vaccine in Chinese Adults Aged ≥50 Years in the US
por: Florea, Ana, et al.
Publicado: (2023)

784. Real-world effectiveness of the mRNA-12733-dose primary series against COVID-19 in an immunocompromised population Interim results from a prospective observational cohort study
por: Ku, Jennifer H, et al.
Publicado: (2022)

07. Recombinant Zoster Vaccine (RZV) Second-Dose Completion in Adults Age 50‒64 Years in the United States
por: Leung, Jessica, et al.
Publicado: (2021)

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

Differences in Estimates of Post-Herpetic Neuralgia Between Medical Chart Review and Self-Report
por: Tanenbaum, Hilary C, et al.
Publicado: (2020)

Text-Based Identification of Herpes Zoster Ophthalmicus With Ocular Involvement in the Electronic Health Record: A Population-Based Study
por: Zheng, Chengyi, et al.
Publicado: (2021)

Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

17. Assessment of Recombinant Zoster Vaccine Second Dose Completion in the United States
por: Patterson, Brandon J, et al.
Publicado: (2020)

115. Post-licensure Safety Study of New-onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis in Adult Recipients of HepB-CPG Vaccine Versus HepB-alum Vaccine
por: Ackerson, Bradley, et al.
Publicado: (2022)

286. Hepatitis B Vaccine Compliance: Comparing 2-Dose and 3-Dose Vaccines
por: Bruxvoort, Katia, et al.
Publicado: (2019)

Risk Factors for Not Completing a 2-Dose Primary Series of Messenger RNA COVID-19 Vaccination in a Large Health Care System in Southern California: Retrospective Cohort Study
por: Xu, Stanley, et al.
Publicado: (2023)

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
por: Bruxvoort, Katia J., et al.
Publicado: (2021)

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study
por: Florea, Ana, et al.
Publicado: (2022)

Severe Morbidity and Mortality Associated With Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults
por: Ackerson, Bradley, et al.
Publicado: (2019)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Challenges in Phase 4 post-licensure safety studies using real world data in the United States: Hepatitis B vaccine example
por: Bruxvoort, Katia, et al.
Publicado: (2021)

Healthy ageing: Herpes zoster infection and the role of the adjuvanted recombinant zoster vaccine
por: Curran, D, et al.
Publicado: (2022)

2284. Ten-Year Effectiveness of Live Virus Herpes Zoster Vaccine
por: Tseng, Hung Fu, et al.
Publicado: (2018)

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older
por: Curran, Desmond, et al.
Publicado: (2019)

Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
por: Slezak, Jeff, et al.
Publicado: (2021)

Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older
por: Cunningham, Anthony L, et al.
Publicado: (2018)

20. Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States
por: Curran, Desmond, et al.
Publicado: (2021)

Multidisciplinary model for administration of recombinant Zoster vaccine in fragile patients
por: Martinelli, S, et al.
Publicado: (2023)

Potential public health impact of the adjuvanted recombinant zoster vaccine among people aged 50 years and older in Beijing
por: Lee, Christa, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

2778. Impact of Reactogenicity on Quality of Life and Physical Functioning in Adults ≥50 Years Receiving Both Doses of the Adjuvanted Recombinant Zoster Vaccine
por: Schmader, Kenneth E, et al.
Publicado: (2019)

08. Concomitant Administration of the Adjuvanted Recombinant Zoster Vaccine (RZV) with 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Is Safe and Does Not Interfere with Immunogenicity of Either Vaccine in Adults Aged ≥ 50 Years
por: Min, Ji-Young, et al.
Publicado: (2021)

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Preventing Varicella-Zoster: Advances With the Recombinant Zoster Vaccine
por: Ilyas, Sahrish, et al.
Publicado: (2020)

2656. Eliciting Preferences for Zoster Vaccination in US Adults Aged 50 Years and Older
por: Patterson, Brandon J, et al.
Publicado: (2019)

36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
por: Baumrin, Emily, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gjo595t6ams6p83eg288ue7ah8